Biotech Values

[ghmm]

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program has completed phase-2b or later and is non-partnered; AND
b) Company lacks the financial resources to commercialize the product on its own.


Edits: Fixed HNAB-Marqibo (2B not 3), Added DYAX-Kalbitor

 
 Company  Product     Phase   Indication (notes) 
 =======  =======     =====   ================== 
 ARNA     Lorcaserin  NDA     Obesity 
 BPAX     Libigel     3       Female Sexual Desire Disorder 
 DDSS     Oleptro     apprvd  Depression (reformltn of generic trazodone) 
 DYAX     Kalbitor    US app  acute hereditary angioedema (seeking x-US partner) 
 HNAB     Marqibo     2B      ALL (ENZN failed accelerated approval in NHL) 
 JAV      Dyloject    NDA     Post-op pain (approved in UK) 
 JAV      Ketamine    3       Acute pain 
 OREX     Contrave    NDA     Obesity 
 OXGN     Zybrestat   3       Anaplastic thyroid cancer 
 MNKD     Afrezza     BLA     Diabetes (CRL rec’d 3/15/10) 
 Pharming Rhucin      BLA     HAE (rejected and resubmitted in EU) 
 SOMX     Silenor     apprvd  Insomnia (low dose of generic doxepin) 
 SVNT     Krystexxa   BLA     Gout (response to CRL submitted 3/30/10) 
 VVUS     Qnexa       NDA     Obesity 
  
  
  
 Procedure for Updating Table 
  
 1. Copy the text in this post into a word processor. 
  
 2. Using a monospace font (e.g. Courier) to facilitate tabular 
 alignment, make your additions and modifications, inserting 
 them in the table in alphabetical order. NOTE: use spaces 
 rather than tab characters. 
  
 3. Add a brief note in the “Edits:” line atop the table to 
 describe your changes. 
  
 4. Insert the iHub formatting directives: Put [ pre ] at the 
 beginning of the table without the surrounding spaces, and 
 put [ /pre ] at the end of the table without the surrounding 
 spaces. 
  
 5. Post your text as a reply to this message. 
  
 Thank you for your cooperation.